WaveMan
WaveMan · Company
FDMT · 4D Molecular Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

FDMT 4D Molecular Therapeutics (FDMT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001650648
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
97
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $319.2K priced

What the filings say about FDMT

Insiders, 180 days
-$5.3M net sold
2 sellers · 42% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.2M
7 notices

4D Molecular Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, 4D Molecular Therapeutics, Inc. insiders sold a net $5.3M of stock across 93 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Bizily Scott
Chief Legal Officer
SELL
2026-10-20 SECtraded 2026-10-16
1,635
$21.0K
-14.4%
Context
  • 39 earlier Form 4 trades (code P or S) here by this insider (39 sales), the last on Sep 16, 2026.
  • The trade is 19.0% of the 8,617 shares held after it.
  • 1 other insider sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Bizily Scott sold about $21.0K of FDMT under a 10b5-1 plan on Oct 16, 2026; 1 other insider sold within 30 days and 97 funds added in the latest 13F quarter.
Kirn David
See Remarks
SELL
2026-10-07 SECtraded 2026-10-05
58,061
$750.2K
-15.0%
Context
  • 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 14, 2026.
  • The trade is 8.2% of the 709,425 shares held after it.
  • 1 other insider sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Kirn David sold about $750.2K of FDMT under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days and 97 funds added in the latest 13F quarter.
Kirn David
See Remarks
SELL
2026-10-07 SECtraded 2026-10-05
272
$3.7K
-15.0%
Context
  • 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 14, 2026.
  • The trade is 0.0% of the 709,153 shares held after it.
  • 1 other insider sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Kirn David sold about $3.7K of FDMT under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days and 97 funds added in the latest 13F quarter.
Bizily Scott
Chief Legal Officer
SELL
2026-09-22 SECtraded 2026-09-16
1,635
$22.3K
-28.0%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 sales), the last on Sep 1, 2026.
  • The trade is 19.0% of the 8,617 shares held after it.
  • 1 other insider sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Bizily Scott sold about $22.3K of FDMT under a 10b5-1 plan on Sep 16, 2026; 1 other insider sold within 30 days and 97 funds added in the latest 13F quarter.
Kirn David
See Remarks
SELL
2026-09-16 SECtraded 2026-09-14
58,333
$811.0K
-26.4%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Aug 19, 2026.
  • The trade is 7.6% of the 767,486 shares held after it.
  • 1 other insider sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Kirn David sold about $811.0K of FDMT under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 97 funds added in the latest 13F quarter.
93 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 88 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.3M over 180 days
-$3.1M over 90 days
below 80% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
97 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
+230194.6% year over year
the highest in Pharma & Biotech
Margin
-164.4% net margin
below 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
26.4% of the float short (float per yahoo 2026-10-26) · 9.3 days to cover · settled 2026-09-30
more than 96% of Pharma & Biotech
What changed in the last 30 days
Oct 20Chief Legal Officer Bizily Scott sold $21.0K under a 10b5-1 plan (Oct 16)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7See Remarks Kirn David sold $753.9K under a 10b5-1 plan (Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Officer David Kirn filed to sell $753.7K by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch FDMT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.7%12M
-32%-1%+29%+59%2025-102025-122026-022026-042026-062026-082026-10 2026-06-22 · Kirn David sold $1.2M2026-09-14 · Kirn David sold $811.0K2026-10-05 · Kirn David sold $750.2K2026-08-19 · Kirn David sold $662.6K2026-07-09 · Kirn David sold $548.2K2026-08-19 · Kirn David sold $425.7K2026-08-04 · Kirn David sold $274.6K2026-07-10 · Kirn David sold $183.6K2026-08-03 · Kirn David sold $124.7K2026-06-23 · Bizily Scott sold $117.7K2026-06-30 · Bizily Scott sold $91.9K2025-10-24 · Bizily Scott sold $32.1K2026-09-16 · Bizily Scott sold $22.3K2026-10-16 · Bizily Scott sold $21.0K2026-08-17 · Bizily Scott sold $19.9K2026-08-13 · Bizily Scott sold $19.6K2026-06-01 · Kirn David sold $19.3K2025-12-16 · Bizily Scott sold $17.8K2025-11-17 · Bizily Scott sold $17.3K2026-09-01 · Bizily Scott sold $8.2K2026-07-10 · Kirn David sold $5.7K2026-10-05 · Kirn David sold $3.7K2025-12-20 · Gupta Ashoo sold $2.7K2026-03-20 · Gupta Ashoo sold $2.7K2026-03-20 · Gupta Ashoo sold $6892025-12-20 · Gupta Ashoo sold $6862026-10-05 · David Kirn filed to sell $753.7K2026-09-14 · David Kirn filed to sell $802.7K2026-08-19 · David Kirn filed to sell $1.2M2026-08-17 · SCOTT BIZILY filed to sell $79.7K2026-08-13 · SCOTT BIZILY filed to sell $19.4K2026-08-04 · David Kirn filed to sell $275.4K2026-08-03 · David Kirn filed to sell $125.3K2026-07-10 · David Kirn filed to sell $193.6K2026-07-09 · David Kirn filed to sell $549.2K2026-06-30 · SCOTT BIZILY filed to sell $84.6K2026-06-23 · SCOTT BIZILY filed to sell $102.2K2026-06-22 · David Kirn filed to sell $1.2M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FDMT: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
5,746,289 sh
$76.5M
RA CAPITAL MANAGEMENT, L.P.
5,049,779 sh
$67.2M
BlackRock, Inc.
4,546,059 sh
$60.5M
GOLDMAN SACHS GROUP INC
4,258,668 sh
$56.6M
NOVO HOLDINGS A/S
3,249,178 sh
$43.2M

Congress trades in FDMT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FDMT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
David Kirn
Filed 2026-10-05
$753.7K
David Kirn
Filed 2026-09-14
$802.7K
David Kirn
Filed 2026-08-19
$1.2M
SCOTT BIZILY
Filed 2026-08-17
$79.7K
SCOTT BIZILY
Filed 2026-08-13
$19.4K

FDMT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$358.3K position · as of 2026-07-31
0.8%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.5M position · as of 2026-05-31
0.4%
T. Rowe Price Health Care ETF
$73.7K position · as of 2026-06-30
0.3%
Small Cap Value Fund
$2.1M position · as of 2026-06-30
0.3%
VOYA SMALL COMPANY PORTFOLIO
$649.9K position · as of 2026-06-30
0.3%
Voya MI Dynamic Small Cap Fund
$434.9K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 10 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 2
2 active
3
Phase 3
3 active
4
Multi-phase
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.3M sold by insiders over 180 days, 97 funds added last quarter, $3.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

FDMT financials

Revenue growth
+230194.6%
XBRL, annual
Net margin
-164.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$92.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-194.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$156.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.05x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-7.97x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-43.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-37.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-44.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$486.8M
market value at close 2026-10-23 on 2024-02-23 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-29.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$85.2M$37.0K$20.7M$3.1M
Operating income-$159.5M-$187.8M-$112.9M-$110.0M
Net income-$140.1M-$160.9M-$100.8M-$107.5M
EPS (diluted)-2.42-2.98-2.58-3.32
Operating cash flow-$109.1M-$134.6M-$75.8M-$86.7M
Cash$60.2M$149.3M$249.1M$52.4M
Long-term debt$0n/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

FDMT Stock Sonar score 6/7 axes

Find similar shapesCompare

FDMT ranks highest on growth (99th percentile) and institutional and government (67th), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
56
Inputs
  • Return on equity-43.3% · 58 pct, sector of 545
  • Return on assets-37.1% · 55 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-44.6% · 55 pct, sector of 576
Financial health
43
Inputs
  • Debt to equity0.05x · 62 pct, sector of 352
  • Cash flow to debt-7.97x · 25 pct, sector of 371
Growth
100
Inputs
  • Revenue growth, YoY+230195% · 100 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.6M · 26 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
67
Inputs
  • Funds adding, latest quarter97 · 67 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
38
Inputs
  • Short interest, % of float+26.4% · 7 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.2% · 70 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

FDMT filings, in plain words

Are 4D Molecular Therapeutics insiders buying or selling FDMT?

In the 180 days to 2026-10-27, 4D Molecular Therapeutics insiders were net sellers, a net $5.3M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of FDMT?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.2M of stock; the latest, by David Kirn, was filed 2026-10-05.

Read the full summary

In the 180 days to 2026-10-27, 4D Molecular Therapeutics insiders were net sellers of FDMT, a net $5.3M across purchases and sales reported on Form 4 by 2 sellers. 42% of the 19 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies